欧美自拍另类欧美宗合图片区,国产视频一区二区三区四区,日本一区二区三区四区视频,婬片一区AAA毛片一区二区

商品編號


AG-20B-0028-C100



品牌


Adipogen



公司


Adipogen



公司分類(lèi)


Antibodies



Size

100 ?g



商品信息


More Information



Product Details



Synonyms

TRAIL Receptor 2; DR5; KILLER; TNFRSF 10B; CD262



Product Type

Monoclonal Antibody



Properties



Clone

TR2.21



Isotype

Mouse IgG1



Source/Host

Purified from concentrated hybridoma tissue culture supernatant.



Immunogen/Antigen

Recombinant human TRAIL-R2 (DR5).



Application


Flow Cytometry

Immunohistochemistry:
(paraffin sections) (20μg/ml)
Optimal conditions must be determined individually for each application.



Crossreactivity

Human



Specificity

Recognizes human TRAIL-R2. Does not cross-react with human TRAIL-R1, -R3 or -R4.



Purity

≥95% (SDS-PAGE)



Purity Detail

Protein G-affinity purified.



Concentration

1mg/ml



Formulation

Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.



Other Product Data

Specially developed for the immunohistochemical detection of TRAIL-R2 in paraffin embedded tissue. Has been shown to detect TRAIL-R2 expressed at endogenous levels in paraffin-embedded tissue in different mammary carcinoma tissues. For IHC (paraffin sections) TRAIL-R2 specific staining protocol (see PDF on web).
UniProt link O14763: human TRAIL-R2




Shipping and Handling



Shipping

BLUE ICE



Short Term Storage

+4°C



Long Term Storage

-20°C



Handling Advice

After opening, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.



Use/St
ABI
lity

Stable for at least 1 year after receipt when stored at -20°C.



Documents



Protocols


Download PDF



MSD
S


Download PDF



Product Specification Sheet



Datasheet


Download PDF





TRAIL-R2 is a receptor for the cytotoxic ligand TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-κB.


Product References

TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window: R. Koschny, et al.; Hepatol.
45,
649 (2007)

Troglitazone-mediated sensitization to TRAILinduced apoptosis is regulated by proteasomedependent degradation of FLIP and ERK1/2- dependent phosphorylation of BAD: K. Grund, et al.; Cancer Biol. Ther.
7,
1982 (2008)

Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer: T. M. Ganten, et al.; J. Mol. Med.
87,
995 (2009)

Prognostic Value of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer: S. Macher-Goeppinger, et al.; Clin. Cancer Res.
15,
650 (2009)

Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma: R. Koschny, et al.; BMC Cancer
13,
532 (2013)

Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis: S. von Karstedt, et al.; Cancer Cell
27,
561 (2015)

IAPs cause resistance to TRAIL-dependent apoptosis in follicular 1 thyroid cancer: T.A. Werner, et al.; Endocr. Relat. Cancer 17, 0479 (2018)